Their Nektar deal is amazing in the fact that they have paid US$1.85b upfront, nearly US$2b more in milestones, but will only get 35% of the drugs profits.
So they are paying masses, but this is for a drug that has been trialed with Opdivo or an Opdivo
/Yervoy combination.
Cavatax has done well with Yervoy alone.
If BMS are happy to pay over $4b Australian to get 35% of Nektar's drug, surely they won't mind going up as high as $1b for 100% of vla's.
Remember it's not only about improving their own drug, but stopping there biggest competitor in this space (Merck) improving theirs.
cheers
VLA Price at posting:
$1.70 Sentiment: Buy Disclosure: Held
